Breaking News on Contract Research, Manufacturing & Clinical Trials

News in brief

Boehringer set to make E.coli for clinical trials


Related topics: Phase I-II, Regulatory affairs, Supply chain, logistics, Contract Manufacturing, Clinical evolution

Molecular Partners has contracted Boehringer Ingelheim to produce a range of highly potent molecules for its clinical pipeline.

Under the deal, Boehringer will manufacture a range of toxic materials including E.coli and other proteins for the DARPin pipeline.

The move the German firm’s recent expansion  of its biomanufacturing facility and mammalian contract manufacturing services in Germany.

Simon Sturge, Boehringer’s corporate senior VP of biopharmaceuticals said: “This agreement reflects the strategy of Boehringer Ingelheim and its new brand Boehringer Ingelheim BioXcellence to be dedicated and committed to the development of highly innovative molecule platforms and projects.”